Login to Your Account

Financings NEWS

Taurx Therapeutics Ltd. closed a $135 million equity financing that will support completion and analysis of phase III trials of the tau aggregation inhibitor, called LMT-X, in Alzheimer's disease.

Quartet Medicine Inc. CEO Kevin Pojasek told BioWorld Today that the finished series A round brought aboard "a financial investor with a long-term view, making sure we can carry this [program] as far as we want, really, into the future" research on tetrahydrobiopterin (BH4) as it relates to chronic pain and inflammation.

Theraclone Sciences Inc. and the University of Texas MD Anderson Cancer Center broadened an informal immuno-oncology (IO) relationship in a big way, jointly launching Oncoresponse Inc. to discover and advance therapeutic antibodies against targets identified during the treatment of cancer patients receiving the IO regimens.

More Financings Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: